Li Hong, Xu Xiaoli, Yan Tong
Department of Integrated Traditional Chinese and Western Medicine Hepatology, Changzhou Third People's Hospital, Changzhou City, Jiangsu Province, 213000, China.
Iran J Public Health. 2025 May;54(5):939-950. doi: 10.18502/ijph.v54i5.18629.
This research's comprehensive review and meta-analysis seek to offer additional non-invasive techniques for diagnosing and monitoring liver fibrosis, thereby serving as a dependable resource for clinical practice and scientific investigation.
To find pertinent research on the use of serum YKL-40 levels in liver fibrosis patients, databases including PubMed, Web of Science, WILEY ONLINE LIBRARY, Scopus, Embase, Cochrane Library, Science Direct, CNKI, Wanfang Data, VIP Information, and the China Biology Medicine Library System were searched. The search was conducted up to May 2024.
In studies comparing serum YKL-40 levels in patients with hepatic fibrosis and controls, the overall combined difference was 1.37 (0.66, 2.08), with the Chinese subgroup showing high heterogeneity, while the Egyptian study did not show heterogeneity. A total of 17 studies, including 2554 patients, were included. The combined sensitivity for diagnosing advanced fibrosis and severe fibrosis was 0.80 and 0.78 respectively, with specificities of 0.88 and 0.82. The AUC for advanced fibrosis and severe fibrosis were 0.91 and 0.87 respectively.
Serum YKL-40 shows potential value in diagnosis of liver fibrosis, but further clinical research is needed to confirm and improve its utility.
本研究的综合综述和荟萃分析旨在提供额外的非侵入性技术用于诊断和监测肝纤维化，从而为临床实践和科学研究提供可靠资源。
为查找关于肝纤维化患者血清YKL-40水平应用的相关研究，检索了包括PubMed、科学网、WILEY ONLINE LIBRARY、Scopus、Embase、Cochrane图书馆、Science Direct、中国知网、万方数据、维普资讯和中国生物医学文献数据库系统在内的数据库。检索截至2024年5月。
在比较肝纤维化患者和对照组血清YKL-40水平的研究中，总体合并差异为1.37（0.66，2.08），中国亚组显示出高度异质性，而埃及的研究未显示出异质性。共纳入17项研究，包括2554例患者。诊断晚期纤维化和重度纤维化的合并敏感性分别为0.80和0.78，特异性分别为0.88和0.82。晚期纤维化和重度纤维化的AUC分别为0.91和0.87。
血清YKL-40在肝纤维化诊断中显示出潜在价值，但需要进一步的临床研究来证实并提高其效用。
